Clinical Trial Update: Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adjuvant toripalimab after surgical resection for esophageal squamous cell carcinoma in patients achieving pathological comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III | Phase 2 | Status: NOT_YET_RECRUITING